Comparing Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization Methods to Determine the HER2/neu Status in Primary Breast Carcinoma using Tissue Microarray

摘要: Identification of HER2/neu status is important for predicting response to specific chemotherapy in breast carcinoma. Chromogenic situ hybridization was performed using tissue microarray technology on 188 primary carcinomas. To validate the reliability novel chromogenic technology, results were correlated with two-color fluorescence done same tumors. On panels containing carcinoma tissues, and conducted simultaneously. amplification detected 46 tumors (24.5%) by 43 (22.9%) hybridization. Results each method agreed other 177 (concordance: 94.1%). associated nuclear pleomorphism (P = .021), poor grade .037). High concordance between indicated that can be a tempting alternative detection because its accuracy relative low cost. appeared have prognostic implication aggressive biologic features Integration enabled high-throughput determination profile rapidity large cohorts